查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1500282

肺炎链球菌疫苗市场：按类型、适应症、年龄层、分布划分 - 2024-2030 年全球预测

Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年肺炎链球菌疫苗市场规模为107.3亿美元，预计2024年将达115.6亿美元，2030年将达183亿美元，复合年增长率为7.92%。

肺炎链球菌疫苗旨在预防链球菌引起的感染疾病。这些感染疾病的范围从耳朵和鼻窦感染疾病到肺炎、脑膜炎和血液感染疾病等严重。这种疫苗对于儿童、老年人和患有某些健康状况且更容易感染这种疾病的人来说至关重要。随着世界人口老化以及越来越多的人面临慢性疾病的风险，肺炎球菌疾病的盛行率不断增加，从而增加了对肺炎球菌疫苗的需求。政府和国际卫生组织对肺炎球菌疫苗的支持正在推动市场成长。这些疫苗通常被纳入国家免疫计划中，因为它们可以降低细菌感染疾病的发生率，尤其是儿童和老年人。人们对免疫重要性的认识不断提高，加上公共卫生宣传活动和教育计画的加强，正在支持肺炎链球菌疫苗市场的成长。高开发成本和复杂的疫苗储存和处理要求阻碍了市场成长。疫苗技术的改进以及针对不同菌株提供广泛保护的结合疫苗的持续开发预计将为肺炎球菌疫苗市场创造机会。

主要市场统计
基准年[2023] 107.3亿美元
预测年份 [2024] 115.6亿美元
预测年份 [2030] 183亿美元
复合年增长率（%） 7.92%

区域洞察

美国拥有发达的医疗保健系统，对疫苗接种方案（包括肺炎球菌疫苗接种，尤其是婴幼儿和老年人）的认知度很高，并且是一个高度发展的新兴市场。将免疫计画纳入公共卫生政策等政策倡议将进一步刺激疫苗接种率。在亚太地区，由于政府在经济开拓、医疗基础设施和疫苗接种方面的政策存在差异，各国的市场动态差异很大。日本、澳洲和韩国等国家由于有利的医疗保健政策和预防保健意识的提高，肺炎链球菌疫苗接种覆盖率很高。另一方面，由于医疗基础设施改善、中等收入群体增加以及政府推广肺炎链球菌感染疫苗接种，印度、日本、中国等新兴国家的疫苗接种率正在迅速上升。欧洲是肺炎球菌疫苗的强大市场，拥有全面的医疗保健系统和广泛的疫苗接种覆盖率。由于医疗保健能力不同以及政府对免疫计划的支持程度不同，中东和非洲的疫苗普及参差不齐。与东欧国家相比，西欧国家的疫苗接种率普遍较高。同时，非洲和中东部分地区仍在继续努力改善疫苗取得和疫苗接种率，这通常得到国际卫生组织的支持。

FPNV定位矩阵

FPNV 定位矩阵对于评估肺炎链球菌疫苗市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对肺炎链球菌疫苗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对当前肺炎球菌疫苗市场地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肺炎链球菌感染的传播
      • 加强有关肺炎链球菌疫苗接种的宣传计划
    • 抑制因素
      • 研发肺炎链球菌疫苗成本高昂
    • 机会
      • 推出新型肺炎链球菌疫苗，针对不同菌株提供更广泛的保护
      • 完善低温运输网络，拓展新型配送体系发展
    • 任务
      • 疫苗生产临床试验处理缓慢
  • 市场区隔分析
    • 类型：增加使用产生强烈免疫反应（包括记忆反应）的结合疫苗
    • 分发：透过政府当局扩大肺炎球菌疫苗的供应，并提高高风险族群的疫苗接种率
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 肺炎链球菌疫苗市场：依类型

  • 结合疫苗
  • 多醣体疫苗

第七章 肺炎链球菌疫苗市场适应症

  • 支气管炎
  • 脑膜炎
  • 肺炎
  • 败血症

第八章肺炎链球菌疫苗市场：依年龄组别

  • 成人
  • 婴幼儿

第九章 肺炎链球菌疫苗市场经销商

  • 政府机关
  • 非政府组织

第十章美洲肺炎链球菌疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太肺炎链球菌疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肺炎链球菌疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准默克公司的新型肺炎球菌疫苗提供广泛保护
    • Vaxcyte 透过加强与 Lonza 在肺炎链球菌疫苗生产方面的合作来加强全球供应链
    • FDA核准辉瑞 Prevenar 20，这是预防肺炎链球菌感染的重大突破
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-43539E5D3200

[184 Pages Report] The Pneumococcal Vaccine Market size was estimated at USD 10.73 billion in 2023 and expected to reach USD 11.56 billion in 2024, at a CAGR 7.92% to reach USD 18.30 billion by 2030.

The pneumococcal vaccine is designed to protect against infections caused by the streptococcus pneumoniae bacteria. These infections range from ear and sinus infections to more severe illnesses, including pneumonia, meningitis, and bloodstream infections. The vaccine is essential for children, the elderly, and individuals with certain health conditions that make them more vulnerable to disease. With the increasing prevalence of pneumococcal diseases as global populations age and more individuals are at risk of chronic diseases, there is an increased need for pneumococcal vaccines. The availability of support from governments and international health organizations for pneumococcal vaccines is driving the market growth. These vaccines are often included in national immunization schedules to reduce the incidence of bacterial infections, especially in children and the elderly. Growing awareness about the importance of immunizations, bolstered by public health campaigns and education programs, supports the growth of the pneumococcal vaccine market. The high development cost and complex vaccine storage and handling requirements hamper the market growth. Rising improvements in vaccine technology and the development of conjugate vaccines that provide broader protection against various strains of bacteria are expected to create opportunities for the pneumococcal vaccine market.

KEY MARKET STATISTICS
Base Year [2023] USD 10.73 billion
Estimated Year [2024] USD 11.56 billion
Forecast Year [2030] USD 18.30 billion
CAGR (%) 7.92%

Regional Insights

America shows a highly developing pneumococcal vaccine market with well-structured healthcare systems and high awareness regarding vaccination protocols, including pneumococcal vaccination, especially for infants and the elderly segment of the population. Policy initiatives, including immunization programs integrated into public health policy, further stimulate vaccine coverage. In APAC, the market dynamics vary widely across countries due to differences in economic development, healthcare infrastructure, and government policies related to vaccinations. Countries such as Japan, Australia, and South Korea exhibit higher adoption rates for pneumococcal vaccines, driven by favorable healthcare policies and a rising awareness of preventive healthcare. Meanwhile, emerging economies such as India, Japan, and China are experiencing rapid growth in vaccine uptake due to improving healthcare infrastructure, increasing middle-class populations, and government immunization drives against pneumococcal diseases. Europe is a strong market for pneumococcal vaccines, supported by comprehensive healthcare systems and wide vaccine coverage. The Middle East and Africa show varied vaccine adoption rates due to contrasting healthcare capabilities and varying levels of government support for immunization programs. Western European countries generally report higher vaccination rates compared to Eastern European nations. Meanwhile, in Africa and some parts of the Middle East, efforts are ongoing to enhance vaccine access and inoculation rates, often supported by international health organizations.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Pneumococcal Vaccine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of pneumococcal diseases
      • Rising awareness programs regarding the use of pneumococcal vaccination
    • Market Restraints
      • High cost associated with the development of pneumococcal vaccines
    • Market Opportunities
      • Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • Improving cold chain networks and growing development of novel delivery systems
    • Market Challenges
      • Slow processing of clinical trials for the production of vaccine
  • Market Segmentation Analysis
    • Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pneumococcal Vaccine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pneumococcal Vaccine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection

The U.S. Food and Drug Administration (FDA) approved Merck's innovative 21-valent pneumococcal conjugate pneumococcal vaccine, designed to offer protection against a comprehensive range of pneumococcal disease strains. This approval underscores a significant advancement in public health, promising enhanced protection for individuals, especially vulnerable populations such as older people and those with compromised immune systems. Merck's vaccine, which has demonstrated efficacy in preventing infections caused by numerous strains of pneumococcal bacteria, aims to reduce the incidence and severity of pneumococcal diseases such as pneumonia, meningitis, and bloodstream infections. [Published On: 2023-12-20]

Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production

Vaxcyte, Inc. is expanding its collaboration with Lonza, a key global player in the pharmaceutical and biotech manufacturing sector, to elevate the production of VAX-24, its 24-valent pneumococcal conjugate vaccine candidate. This strategic partnership aims to reinforce Vaxcyte's manufacturing capabilities to meet global commercial demands, anticipating the transition into the pivotal Phase 3 vaccine trial. This collaboration underscores both companies' commitment to addressing the wide-ranging pneumococcal disease threat with a next-generation vaccine that could significantly impact public health worldwide. [Published On: 2023-10-16]

FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention

The U.S. Food and Drug Administration (FDA) has recently approved Prevnar 20, a novel 20-valent pneumococcal conjugate vaccine developed by Pfizer. This approval marks a significant milestone in preventing pneumococcal diseases, as Prevnar 20 is designed to protect against twenty pneumococcal serotypes responsible for most pneumococcal disease cases and pneumonia. The vaccine is authorized for use in adults aged 18 years and older, offering enhanced coverage and aiming to improve public health outcomes by reducing the incidences of these severe infections. This development is particularly timely, considering the substantial health burden pneumococcal diseases place on individuals and healthcare systems globally. [Published On: 2023-04-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pneumococcal Vaccine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Pneumococcal Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biological E. Limited, Biovac, CSL Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Incepta Pharmaceuticals Ltd., Lonza AG, Merck & Co., Inc., Panacea Biotec Limited, Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pneumococcal Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Conjugate Vaccines
    • Polysaccharide Vaccines
  • Indication
    • Bronchitis
    • Meningitis
    • Pneumonia
    • Sepsis
  • Age Group
    • Adults
    • Infants & Young Children
  • Distribution
    • Government Authorities
    • Non-Governmental Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pneumococcal diseases
      • 5.1.1.2. Rising awareness programs regarding the use of pneumococcal vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of pneumococcal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • 5.1.3.2. Improving cold chain networks and growing development of novel delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of vaccine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • 5.2.2. Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Pneumococcal Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Conjugate Vaccines
  • 6.3. Polysaccharide Vaccines

7. Pneumococcal Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Bronchitis
  • 7.3. Meningitis
  • 7.4. Pneumonia
  • 7.5. Sepsis

8. Pneumococcal Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Infants & Young Children

9. Pneumococcal Vaccine Market, by Distribution

  • 9.1. Introduction
  • 9.2. Government Authorities
  • 9.3. Non-Governmental Organizations

10. Americas Pneumococcal Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumococcal Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumococcal Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection
    • 13.3.2. Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production
    • 13.3.3. FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PNEUMOCOCCAL VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMOCOCCAL VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PNEUMOCOCCAL VACCINE MARKET DYNAMICS
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 69. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 121. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 129. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 137. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 153. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 169. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 177. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 185. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 203. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 211. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 219. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 227. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 235. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 243. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 251. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 267. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 275. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 283. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 291. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 299. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 323. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 331. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 347. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. UNI